InnoPharma is a unit of PFE, the result of a 2014 acquisition (#msg-104352638).
Three companies other than PFE who have filed paragraph-IV challenges on Restasis—TEVA, MYL, and AKRX—have not (yet) settled with AGN.
The provision in the PR above regarding the launch of an authorized generic is presumably triggered if a company other than PFE launches its own generic Restasis.
Restasis is AGN’s second-largest product (after Botox).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.